Header cover image

Market Cap


Last Updated

2021/09/16 15:35 UTC

Data Sources

Company Financials +

Executive Summary

OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide. More Details

Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has OK Biotech's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: 4155 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4155's weekly volatility (3%) has been stable over the past year.

Market Performance

7 Day Return




TW Medical Equipment


TW Market

1 Year Return




TW Medical Equipment


TW Market

Return vs Industry: 4155 underperformed the TW Medical Equipment industry which returned 7% over the past year.

Return vs Market: 4155 underperformed the TW Market which returned 34.2% over the past year.

Shareholder returns

7 Day-1.1%0.4%0.2%
30 Day-2.2%3.0%4.2%
90 Day-14.0%-7.4%0.2%
1 Year-25.9%-29.9%10.0%7.0%38.1%34.2%
3 Year7.1%-10.7%23.0%12.6%78.2%59.9%
5 Year5.9%-19.7%8.9%-6.2%122.9%85.5%

Long-Term Price Volatility Vs. Market

How volatile is OK Biotech's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is OK Biotech undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 4155 (NT$22.05) is trading below our estimate of fair value (NT$30.17)

Significantly Below Fair Value: 4155 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 4155's PE Ratio (22.7x) is in line with the TW Medical Equipment industry average.

PE vs Market: 4155 is poor value based on its PE Ratio (22.7x) compared to the TW market (16.4x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4155's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 4155 is good value based on its PB Ratio (1.3x) compared to the TW Medical Equipment industry average (2.1x).

Future Growth

How is OK Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OK Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has OK Biotech performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4155 has high quality earnings.

Growing Profit Margin: 4155's current net profit margins (6.6%) are lower than last year (10.3%).

Past Earnings Growth Analysis

Earnings Trend: 4155's earnings have grown by 4.3% per year over the past 5 years.

Accelerating Growth: 4155's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4155 had negative earnings growth (-34.2%) over the past year, making it difficult to compare to the Medical Equipment industry average (9.5%).

Return on Equity

High ROE: 4155's Return on Equity (4.7%) is considered low.

Financial Health

How is OK Biotech's financial position?

Financial Position Analysis

Short Term Liabilities: 4155's short term assets (NT$1.5B) exceed its short term liabilities (NT$664.1M).

Long Term Liabilities: 4155's short term assets (NT$1.5B) exceed its long term liabilities (NT$427.3M).

Debt to Equity History and Analysis

Debt Level: 4155's debt to equity ratio (30.4%) is considered satisfactory.

Reducing Debt: 4155's debt to equity ratio has reduced from 33.3% to 30.4% over the past 5 years.

Debt Coverage: 4155's debt is not well covered by operating cash flow (1.9%).

Interest Coverage: 4155's interest payments on its debt are well covered by EBIT (14.3x coverage).

Balance Sheet


What is OK Biotech current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 4155's dividend (6.35%) is higher than the bottom 25% of dividend payers in the TW market (1.94%).

High Dividend: 4155's dividend (6.35%) is in the top 25% of dividend payers in the TW market (5.26%)

Stability and Growth of Payments

Stable Dividend: 4155's dividend payments have been volatile in the past 10 years.

Growing Dividend: 4155's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (140.1%), 4155's dividend payments are not well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


OK Biotech has no CEO, or we have no data on them.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

OK Biotech Co., Ltd.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: OK Biotech Co., Ltd.
  • Ticker: 4155
  • Exchange: TWSE
  • Founded: 2006
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: NT$2.077b
  • Shares outstanding: 94.18m
  • Website:


  • OK Biotech Co., Ltd.
  • No. 91, Gongdao 5th Road
  • Sec. 2
  • Hsinchu City
  • 30070
  • Taiwan



OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide. It also provides nebulizers, glucometers, blood sugar meters, blood glucose test strips, and personal sound amplifiers. The compa...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 15:35
End of Day Share Price2021/09/16 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.